Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19;10(10):2188.
doi: 10.3390/jcm10102188.

Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease

Nicole Ng  1 , Charles A Powell  1
Affiliations
Review

Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease

Nicole Ng et al. J Clin Med. .

Abstract

Severe coronavirus disease 2019 causes multi-organ dysfunction with significant morbidity and mortality. Mounting evidence implicates maladaptive over-activation of innate immune pathways such as the complement cascade as well as endothelial dysfunction as significant contributors to disease progression. We review the complement pathways, the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on these pathways, and promising therapeutic targets in clinical trials.

Keywords: COVID-19; SARS-CoV-2; complement inhibitor; complement pathway; lectin pathway; mannose-associated serine protease inhibitor.

PubMed Disclaimer

Conflict of interest statement

C.A.P. is supported by an NIH grant (5R01HL130826) and is the principal investigator at the Mount Sinai Hospital for the expanded access program of eculizumab (NCT04355494) and the phase III clinical trial of ravulizumab (NCT04570397) in severe COVID-19. N.N. is a co-investigator for both studies. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Complement activation pathways. The classical pathway is activated by the binding of antibody-antigen complex with the C1 esterase complex (C1qC1rC1s), which then forms C3 convertase (C4b2a). The lectin pathway is initiated by the binding of mannose-binding lectin with mannose residues on pathogen surfaces, which activates mannose-associated serine proteases (MASPs) to form the same C3 convertase (C4b2a). The alternative pathway is triggered directly by antigen and also through spontaneous autoactivation, leading to the formation of a similar C3 convertase (C3bBb). These C3 convertases hydrolyze C3 to yield the C5 convertases (C4b2a3b and C3bBbC3b, respectively), which culminates in the generation of C5b-9 or MAC (membrane attack complex).
Figure 2
Figure 2
Integration between the complement and coagulation cascades. Relationship between the complement and coagulation cascades, as well as platelet activation is highlighted. Most notable are the effects of MASPs on thrombin, factor XIIIa, and fibrinogen; C5a on tissue factor; and C5b-9 on thrombin. Adapted from Hill et al. [23].
Figure 3
Figure 3
Mannose-binding lectin pathway and downstream effects. Initiation of the lectin pathway leads to the activation of MASP-1, which is capable of further autoactivation as well as activation of MASP-2. MASP-2 is responsible for the generation of subsequent anaphylatoxins and MAC. MASP-1 has much more relaxed substrate specificity, rendering additional effects in the coagulation and inflammatory cascades. Adapted from Dobo et al. [25].
Figure 4
Figure 4
Therapeutic targets in the complement cascade for the treatment of coronavirus disease 2019 (COVID-19) pneumonia.
See this image and copyright information in PMC

References

    1. Chaplin H. Review: The burgeoning history of the complement system 1888–2005. Immunohematology. 2005;21:85–93. - PubMed
    1. Ghebrehiwet B. The complement system: An evolution in progress. F1000Research. 2016;5:2840. doi: 10.12688/f1000research.10065.1. - DOI - PMC - PubMed
    1. Tegla C.A., Cudrici C., Patel S., Trippe R., Rus V., Niculescu F., Rus H. Membrane attack by complement: The assembly and biology of terminal complement complexes. Immunol. Res. 2011;51:45–60. doi: 10.1007/s12026-011-8239-5. - DOI - PMC - PubMed
    1. Dunkelberger J.R., Song W.-C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50. doi: 10.1038/cr.2009.139. - DOI - PubMed
    1. Stoermer K.A., Morrison T.E. Complement and viral pathogenesis. Virology. 2011;411:362–373. doi: 10.1016/j.virol.2010.12.045. - DOI - PMC - PubMed

LinkOut - more resources